GlassScriptPhysician profile
Esther Fischer
NPI 1942643747
$1,825.37
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.93 · 2021: $242 · 2022: $1,453 · 2023: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.21 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $340.26 | 2022 | |
| Biogen, INC. | $176.57 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $148.86 | 2021-2022 | |
| Livanova USA, INC. | $80.08 | 2022 | |
| Acorda Therapeutics, INC | $58.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $55.52 | 2022 | |
| Lundbeck LLC | $48.83 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $48.78 | 2021-2022 | |
| Genzyme Corporation | $47.32 | 2022 | |
| Neurocrine Biosciences, INC. | $45.54 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $41.17 | 2021 | |
| Allergan, INC. | $39.22 | 2022 | |
| Tanabe Pharma America, INC. | $37.34 | 2022 | |
| Acadia Pharmaceuticals INC | $36.60 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.10 | 2022 | |
| Jazz Pharmaceuticals INC. | $29.93 | 2019 | |
| Avanir Pharmaceuticals, INC. | $26.76 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $25.35 | 2022 | |
| Ucb, INC. | $24.21 | 2021-2022 | |
| Amylyx Pharmaceuticals, INC. | $21.34 | 2023 | Relyvrio |
| Harmony Biosciences LLC | $18.80 | 2022 | |
| Lilly USA, LLC | $16.99 | 2022 | |
| Emd Serono, INC. | $15.16 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $14.68 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.03 | 2022 | |
| Neurelis, INC. | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.